bemarituzumab

Bemarituzumab is a first-in-class, humanized, afucosylated IgG1 kappa monoclonal antibody that selectively targets the extracellular domain of fibroblast growth factor receptor 2b (FGFR2b), a splice variant of FGFR2. By binding to FGFR2b, it blocks fibroblast growth factors from activating the receptor, thereby inhibiting downstream pro-tumor signaling pathways and potentially slowing cancer progression. Bemarituzumab also enhances antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing FGFR2b. It is being developed primarily for the treatment of previously untreated locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma with FGFR2b overexpression, in combination with chemotherapy. The drug is also under investigation for other solid tumors that overexpress FGFR2b[3][5][8].

Other names

bemarituzumab